3 research outputs found
Palladium-Catalyzed Ring-Forming Alkene Aminoaroylation of Unsaturated Hydrazones and Sulfonamides
The
first example of a PdÂ(OAc)<sub>2</sub>-catalyzed ring-forming
alkene aminoaroylation of unsaturated hydrazones and sulfonamides
is described. This protocol features the use of diaryliodonium salts
as both oxidants and aryl sources, thus enabling mild reaction conditions,
good chemoselectivity, a broad substrate scope, and high functional
group tolerance. A wide range of synthetically and biologically important
functionalized dihydropyrazoles and isoxazolidines have been obtained
in good yields
Synthesis of Dihydropyrazoles via Ligand-Free Pd-Catalyzed Alkene Aminoarylation of Unsaturated Hydrazones with Diaryliodonium Salts
A ligand-free, palladium-catalyzed
aminoarylation reaction of the
unactivated alkenes in β,γ-unsaturated hydrazones is described.
This protocol enables efficient and simultaneous formation of CÂ(sp<sup>3</sup>)–N and CÂ(sp<sup>3</sup>)–CÂ(sp<sup>2</sup>)
bonds under mild conditions, providing a practical and general approach
to various diversely substituted dihydropyrazoles in generally good
yields, without the use of any stoichiometric external oxidant
Data_Sheet_1_Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers.docx
Background and objectiveGestational diabetes mellitus (GDM) “programs” an elevated risk of metabolic dysfunctional disorders in the offspring, and has been associated with elevated leptin and decreased adiponectin levels in cord blood. We sought to assess whether docosahexaenoic acid (DHA) supplementation in GDM affects neonatal metabolic health biomarkers especially leptin and adiponectin.MethodsIn a randomized controlled trial, singleton pregnant women with de novo diagnosis of GDM at 24–28  weeks of gestation were randomized to dietary supplementation of 500 mg DHA per day (intervention, n = 30) until delivery or standard care (control, n = 38). The primary outcomes were cord blood leptin and total adiponectin concentrations. Secondary outcomes included high-molecular-weight (HMW) adiponectin and insulin-like growth factor-1 (IGF-1) concentrations in cord blood, maternal glycemic control post-intervention and birth weight (z score). In parallel, 38 euglycemic pregnant women were recruited for comparisons of cord blood biomarkers.ResultsThere were no significant differences in cord serum leptin, total and HMW adiponectin and IGF-1 concentrations between DHA supplementation and control groups (all p > 0.05). Maternal fasting and 2-h postprandial blood glucose levels at 12–16 weeks post-intervention were similar between the two groups. The newborns in the DHA group had higher birth weight z scores (p = 0.02). Cord blood total and HMW adiponectin concentrations were significantly lower in GDM vs. euglycemic pregnancies.ConclusionDocosahexaenoic acid supplementation at 500  mg/day in GDM women did not affect neonatal metabolic biomarkers including leptin, adiponectin and IGF-1. The results are reassuring in light of the absence of influence on neonatal adipokines (leptin and adiponectin), and potential benefits to fetal growth and development.Clinical Trial Registration: Clinicaltrials.gov, NCT03569501.</p